Top 10 at 10: REE-nergised rare earths explorers, biotech standouts lead Wednesday’s winners

Estimated read time 2 min read

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data.

It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.

The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has started trading.

 

WINNERS

Stocks highlighted in yellow made market-moving announcements (click headings to sort).

Security Description Last % Volume MktCap DES Desoto Resources 0.13 71% 1,973,098 $4,554,414 OD6 OD6 Metals 0.087 38% 926,862 $5,056,060 COV Cleo Diagnostics 0.23 35% 455,650 $12,597,000 OAR OAR Resources Ltd 0.002 33% 1,447,500 $4,729,966 TX3 Trinex Minerals Ltd 0.004 33% 3,997,250 $5,485,957 BEZ Besra Gold Inc 0.11 24% 1,654,058 $37,210,981 VTI Vision Tech Inc 0.135 23% 71,915 $6,023,147 8IH 8I Holdings Ltd 0.012 20% 30,100 $3,573,560 CAV Carnavale Resources 0.006 20% 4,471 $17,117,759 LRL Labyrinth Resources 0.006 20% 100,000 $5,937,719

WordPress Table Plugin

Desoto Resources (ASX:DES) is buying a rare earths project in the Northern Territory called Spectrum, where previous drilling pulled up a highlight 6m @ 6.55% total rare earths (TREO) from 248m.

OD6 Metals (ASX:OD6) doubles the resource at its Splinter Rock project to 682Mt @ 1,338ppm TREO.

“This mineral resource estimate sets OD6 apart from any other clay hosted rare earth project in Australia, and highlights Splinter Rock to be one of the largest and highest-grade projects globally,” MD Brett Hazelden says.

Oar Resources (ASX:OAR) increases its uranium exploration ground by 283% to 880sqkm in the Brazilian states of Rio Grande Do Sul and Goiás.

Cleo Diagnostic’s (ASX:COV) ovarian cancer blood test outperforms the current clinical benchmark, correctly detecting 90% of early-stage cancers compared to only 50% using standard workflows.

Genetic Technologies (ASX:GTG) releases its novel Comprehensive Risk Assessment test that covers 100% of women at risk of developing breast and ovarian cancer.

“… in preparation for significant demand for this revolutionary test we have fully onboarded a high throughput automated laboratory in the United States with capacity to scale up to run 100,000 tests per month should future demand require,” GTG chair Peter Rubinstein says.

 

LOSERS

Stocks highlighted in yellow made market-moving announcements (click headings to sort).

Security Description Last % Volume MktCap 88E 88 Energy Ltd 0.002 -33% 977999 $86,678,016 TKL Traka Resources 0.001 -33% 322518 $2,625,988 AVE Avecho Biotech Ltd 0.003 -25% 220000 $12,677,188 SFG Seafarms Group Ltd 0.003 -25% 20000 $19,346,397 AIV Activex Limited 0.004 -20% 9822 $1,077,513 1MC Morella Corporation 0.0025 -17% 2901833 $18,536,398 MTL Mantle Minerals Ltd 0.0025 -17% 1050000 $18,592,338 PNT Panther Metals 0.05 -15% 169491 $5,142,804 MCL Mighty Craft Ltd 0.006 -14% 48950 $2,582,365 TSL Titanium Sands Ltd 0.006 -14% 4475000 $15,482,230

WordPress Table Plugin

The post Top 10 at 10: REE-nergised rare earths explorers, biotech standouts lead Wednesday’s winners appeared first on Stockhead.

You May Also Like